These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 10740398)

  • 41. On the clinical meaningfulness of a treatment's effect on a time-to-event variable.
    Snapinn S; Jiang Q
    Stat Med; 2011 Aug; 30(19):2341-8. PubMed ID: 21520457
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Patients 65 years of age or older in cancer-treatment trials.
    Bartlett EE
    N Engl J Med; 2000 May; 342(20):1531. PubMed ID: 10819657
    [No Abstract]   [Full Text] [Related]  

  • 43. [Prognostic factors in malignant tumors--significance for quality management].
    Hermanek P
    Z Arztl Fortbild Qualitatssich; 1997 Jun; 91(3):289-92. PubMed ID: 9312435
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [ESMO 2004. Comparative studies delineating future options in the treatment of solid tumors].
    Mansueto G; Longo F
    Tumori; 2005; 91(1):suppl 21-35. PubMed ID: 15850021
    [No Abstract]   [Full Text] [Related]  

  • 45. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables.
    Anderson JR; Cain KC; Gelber RD
    J Clin Oncol; 2008 Aug; 26(24):3913-5. PubMed ID: 18711176
    [No Abstract]   [Full Text] [Related]  

  • 46. Limitations and advantages of meta-analysis in clinical trials.
    Rockette HE; Redmond CK
    Recent Results Cancer Res; 1988; 111():99-104. PubMed ID: 3175314
    [No Abstract]   [Full Text] [Related]  

  • 47. Participation of adolescents with cancer in clinical trials.
    Ferrari A; Bleyer A
    Cancer Treat Rev; 2007 Nov; 33(7):603-8. PubMed ID: 17250970
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Data Monitoring Committees and early stopping guidelines: the Southwest Oncology Group experience.
    Crowley J; Green S; Liu PY; Wolf M
    Stat Med; 1994 Jul 15-30; 13(13-14):1391-9. PubMed ID: 7973218
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Statistical tools for subset analysis in clinical trials.
    Simon R
    Recent Results Cancer Res; 1988; 111():55-66. PubMed ID: 3051230
    [No Abstract]   [Full Text] [Related]  

  • 50. Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research.
    Fleming TR; Prentice RL; Pepe MS; Glidden D
    Stat Med; 1994 May; 13(9):955-68. PubMed ID: 8047747
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New response criteria proposed for immunotherapies.
    Tuma RS
    J Natl Cancer Inst; 2008 Sep; 100(18):1280-1. PubMed ID: 18780859
    [No Abstract]   [Full Text] [Related]  

  • 52. ['94 oncology update].
    Pfreundschuh M
    Med Klin (Munich); 1996 Apr; 91 Suppl 1():7-22. PubMed ID: 8657089
    [No Abstract]   [Full Text] [Related]  

  • 53. Immunotherapy exploiting the versatility of dendritic cells.
    Kadowaki N
    Ther Apher Dial; 2003 Jun; 7(3):312-7. PubMed ID: 12924606
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Measuring health-related quality of life in clinical trials that evaluate the role of chemotherapy in cancer treatment.
    Michael M; Tannock IF
    CMAJ; 1998 Jun; 158(13):1727-34. PubMed ID: 9676550
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A community hospital clinical trials program: infrastructure for growth.
    Barr LH; Crofton J; Annie Lin YH
    Surg Oncol Clin N Am; 2011 Jul; 20(3):447-53, vii- viii. PubMed ID: 21640914
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New horizons on the landscape of AYA oncology.
    Barr RD; Bleyer WA
    Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28741306
    [No Abstract]   [Full Text] [Related]  

  • 57. Overoptimism over cancer.
    McVie JG
    Lancet; 2000 Mar; 355(9207):925-6. PubMed ID: 10752722
    [No Abstract]   [Full Text] [Related]  

  • 58. Cost effectiveness of sunitinib.
    Trippoli S; Messori A
    J Clin Oncol; 2008 Dec; 26(35):5829; author reply 5829-30. PubMed ID: 19001342
    [No Abstract]   [Full Text] [Related]  

  • 59. Restricted Mean Survival Time: An Obligatory End Point for Time-to-Event Analysis in Cancer Trials?
    A'Hern RP
    J Clin Oncol; 2016 Oct; 34(28):3474-6. PubMed ID: 27507871
    [No Abstract]   [Full Text] [Related]  

  • 60. Endpoints in cancer clinical trials.
    Fiteni F; Westeel V; Pivot X; Borg C; Vernerey D; Bonnetain F
    J Visc Surg; 2014 Feb; 151(1):17-22. PubMed ID: 24440056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.